tirzepatide consent FDA Grants a New Indication for Obesity Management Tirzepatide Weight Loss Injection Form

Biotechnology & Bioengineering 96 : 722737

All methods are reported in accordance with ARRIVE guidelines

GLP-1 can contribute to both: on the one hand, by promoting stopping eating, and on the other hand, by prolonging the feeling of a "full tank" via slower digestion

doi: 10.1210/clinem/dgz175 Summary Keywords dual agonists, incretin based therapy, tirzepatide, type 2 diabetes, obesity, glucagon-like peptide-1 receptor agonists Citation Zeng Q, Xu J, Mu X, Shi Y, Fan H and Li S (2023) Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis